Curie Capital

Curie Capital is a life science focused venture capital firm founded in 2018. It is a new and dynamic investment fund with a personal touch. Curie Capital is based in Amsterdam and invests in early stage companies with talented teams and exciting science and technology. The founding partners Mariette van der Velden and Han de Groot both have extensive experience in investing, entrepreneurship and managing companies across the full life cycle from startup to (public) exit. The partners leverage their complementary skills and network for the success of their portfolio companies.

Mariette van der Velden

Partner

5 past transactions

TargED Biopharmaceuticals

Series A in 2022
TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.

Sirius Medical

Series A in 2021
Developer of tumor localization technology designed to improve care for cancer patients. The company's technology uses a tiny implanted magnetic seed to precisely mark the tumor and a detection probe to accurately locate the seed during surgery, enabling patients to receive affordable cancerous tumor surgery and improved surgical care.

TargED Biopharmaceuticals

Seed Round in 2020
TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.

Sirius Medical

Series A in 2020
Developer of tumor localization technology designed to improve care for cancer patients. The company's technology uses a tiny implanted magnetic seed to precisely mark the tumor and a detection probe to accurately locate the seed during surgery, enabling patients to receive affordable cancerous tumor surgery and improved surgical care.

Citryll

Series A in 2019
Citryll is a private pharmaceutical company that develops pharmaceutical drugs used to treat autoimmune and other human diseases. The company offers formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes that enable doctors to help in the treatment of lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis. Citryll was established in 2015 and is headquartered in Oss, The Netherlands.